Overview
Transient neonatal myasthenia gravis (also called transient neonatal MG) is a temporary condition that affects newborn babies born to mothers who have myasthenia gravis. Myasthenia gravis is an autoimmune disease where the mother's immune system makes antibodies that attack the connections between nerves and muscles. During pregnancy, these antibodies can cross the placenta and enter the baby's bloodstream. After birth, these maternal antibodies cause the baby to have muscle weakness and difficulty with basic functions like feeding, breathing, and moving. The most common symptoms include a weak cry, poor sucking and feeding ability, general floppiness (low muscle tone), and sometimes breathing difficulties. The baby may also have a less expressive face and reduced movement of the arms and legs. Symptoms usually appear within the first few hours to days after birth. The good news is that this condition is temporary. As the mother's antibodies naturally break down and leave the baby's body over the first few weeks of life, the symptoms gradually improve and eventually go away completely. Treatment is supportive and may include help with feeding, breathing support if needed, and sometimes medications like anticholinesterase drugs (such as pyridostigmine or neostigmine) to temporarily improve muscle strength. Most babies recover fully within two to four weeks, though some may take up to a few months. The condition does not come back once it resolves, and the child's long-term development is typically normal.
Also known as:
Key symptoms:
Weak or feeble cryPoor sucking and difficulty feedingGeneral floppiness or low muscle toneBreathing difficultiesReduced facial expressionsDecreased movement of arms and legsDrooping eyelidsDifficulty swallowingNeed for breathing supportWeak grasp reflex
Sporadic
Usually appears on its own, not inherited from a parent
Neonatal
Begins at or shortly after birth (first 4 weeks)
FDA & Trial Timeline
7 eventstreatment of generalized myasthenia gravis (gMG) in adult and pediatric patients 12 years of age and older who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive
Treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive
treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive
treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive
treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive
SOLIRIS: FDA approved
for the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
10 availableBKEMV
The treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
Uplizna
indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (MuSK) antibody positive
EPYSQLI
the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive
Ultomiris
the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive
Imaavy
treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients 12 years of age and older who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) ant…
treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients 12 years of age and older who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive
Zilbrysq
Treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive
Rystiggo
treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive
Vyvgart Hytrulo
treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive
Vyvgart
treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive
SOLIRIS
for the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive
Clinical Trials
View all trials with filters →No actively recruiting trials found for Transient neonatal myasthenia gravis at this time.
New trials open frequently. Follow this disease to get notified.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Financial Resources
5 resourcesTravel Grants
No travel grants are currently matched to Transient neonatal myasthenia gravis.
Community
No community posts yet. Be the first to share your experience with Transient neonatal myasthenia gravis.
Start the conversation →Latest news about Transient neonatal myasthenia gravis
1 articlesCaregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.How severe is my baby's condition, and will they need breathing support?,How long do you expect the symptoms to last in my baby's case?,Will my baby need medication, and if so, what are the side effects?,How will feeding be managed while my baby is recovering?,Are there any long-term effects I should watch for as my child grows?,If I have another pregnancy, what is the chance that the next baby will also be affected?,What warning signs should I watch for at home after discharge?
Common questions about Transient neonatal myasthenia gravis
What is Transient neonatal myasthenia gravis?
Transient neonatal myasthenia gravis (also called transient neonatal MG) is a temporary condition that affects newborn babies born to mothers who have myasthenia gravis. Myasthenia gravis is an autoimmune disease where the mother's immune system makes antibodies that attack the connections between nerves and muscles. During pregnancy, these antibodies can cross the placenta and enter the baby's bloodstream. After birth, these maternal antibodies cause the baby to have muscle weakness and difficulty with basic functions like feeding, breathing, and moving. The most common symptoms include a we
How is Transient neonatal myasthenia gravis inherited?
Transient neonatal myasthenia gravis follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Transient neonatal myasthenia gravis typically begin?
Typical onset of Transient neonatal myasthenia gravis is neonatal. Age of onset can vary across affected individuals.
Which specialists treat Transient neonatal myasthenia gravis?
15 specialists and care centers treating Transient neonatal myasthenia gravis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.
What treatment and support options exist for Transient neonatal myasthenia gravis?
5 patient support programs are currently tracked on UniteRare for Transient neonatal myasthenia gravis. See the treatments and support programs sections for copay assistance, eligibility, and contact details.